A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044
Original registry description
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
Recruitment has ended for the Phase 1 portion of the study and will reopen when Phase 2 begins recruitment.